Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCiro R. RinaldiLCLynette CheeFPFrancesca Palandri

Discussion

Loading...

Member takes

Overview

Observational analysis shows elritercept improves anemia and hematopoiesis in myelofibrosis patients receiving ruxolitinib, suggesting new treatment options.

Key Points

  • Significant improvements in anemia and hematopoiesis observed in patients receiving ruxolitinib and elritercept.
  • By week 24, 30.4% of transfusion-dependent patients achieved RBC transfusion independence and clinically relevant hemoglobin increases.
  • Phase 2 open-label evaluation assessed safety and efficacy for elritercept combination with ruxolitinib in myelofibrosis patients.
  • Findings support elritercept's role as a differentiated therapy in managing anemia in myelofibrosis cases.

Cite This Study

Rinaldi et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de47https://doi.org/10.1182/blood-2025-909
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dose intensive regimen of CK0804 tregs in myelofibrosis2025
  2. 2A phase I study of the combination of ruxolitinib and the ERK1/2 inhibitor ulixertinib in previously treated myelofibrosis patients.2025
  3. 3Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study2025 · 6 citations
  4. 4Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients2025 · 1 citations
  5. 5Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation2025 · 6 citations